Yearly Archives: 2023

SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an organization committed to democratizing clinical trials by providing full-service support to trial investigators in community settings, is pleased to announce Kristin Andruska, MD, PhD has been appointed Senior Medical Director of Clinical Neuroscience and Scientific Research Director. Dr. Andruska will be pivotal in offering expert medical and clinical support for upcoming & ongoing trials at Adaptive Research, particularly those in movement disorders and neurodegenerative diseases."The growth of Adaptive Research is not just about expanding our team, but also about deepening our expertise," said Deepak Behera, MD, President and CEO. "With Kristin's comprehensive experience in clinical settings and in conducting clinical trials, she is ideally suited to bolster our clinical trial operations. We look forward to growing our community clinical trial network further in the coming months, which becomes more important in light of recent FDA guidelines highlighting a growing need for inclusion of clinical trial data from diverse patient populations."Kristin Andruska is a board-certified neurologist, a fellowship-trained movement disorders specialist, and a renowned expert in the field of neurodegenerative disease. Concurrent to her position at Adaptive Research, she serves as head of the California Movement Disorders Center and as an advisor for therapeutics and technologies in the neurodegenerative space. Previously, Dr. Andruska was the Medical Director of the Movement Disorders Clinic at the Parkinson’s Institute and Clinical Center, where she also led a robust clinical research program. She attended the University of Minnesota as a predoctoral fellow of the National Institute of Health’s Medical Scientist Training Program, earning both an MD and a PhD. She received a competitive Kirschstein fellowship to support her PhD research, which focused on the biochemistry of inherited neurodegenerative disease. Dr. Andruska completed her neurology residency at Washington University in Saint Louis, where she was…

SAN FRANCISCO and DALY CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose to democratize clinical trials by integrating community physicians into the clinical trial process, and AHMC Seton Medical Center, a full-service, community based hospital offering a comprehensive range of medical specialties, today announced a collaboration to expand clinical trial access at AHMC Seton Medical Center. Seton Medical Center is recognized for its stroke treatment and cardiovascular excellence, including STEMI certification. Seton offers a comprehensive range of medical specialties on both an inpatient and outpatient basis, as well as emergency and surgical services. Seton also provides Acute Psychiatry, Wound Care, Radiation Oncology, Subacute, Skilled Nursing and Laboratory and Imaging services for the community. Through this partnership, pharmaceutical companies and clinical research organizations (CROs) may utilize Seton as a clinical trial site for investigative trials if their studies align with Seton’s patient population and the interest of patients in participating.   “Seton’s high quality medical staff and excellent reputation in the community are a welcome addition to our network of clinical trial sites,” said Deepak Behera, MD, President and Chief Executive Officer. “Because Seton treats patients with a broad array of needs from the emergency room to outpatient services, we are able to significantly expand the potential therapeutic areas available to our clients.” Sarkis Vartanian, Administrator of AHMC Seton Medical Center, added, “We are excited to partner with Adaptive Research to offer clinical trials on our campus. At Seton, we pride ourselves on innovation when it comes to patient care and this arrangement provides another unique offering for our community.” About AHMC Seton Medical Center AHMC Seton Medical Center has been serving the health care needs of San Francisco and northern San Mateo County since its founding as Mary’s Help Hospital in…

SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose to democratize clinical trials by integrating community physicians into the clinical trial process, today announced that Perminder Bhatia, M.D. has been appointed as Head of Neurology reporting to the Chief Medical Officer.  “2022 was a year of tremendous growth for Adaptive Research and with our continued expansion we are thrilled to have Perminder join our team,” said Brajesh Agrawal, M.D., Chief Medical Officer. “His extensive experience in neurology combined with his proficiency in conducting clinical trials makes him the ideal candidate to lead our neurology division. Dr. Bhatia’s appointment enhances our ability to deliver neurology trials across our network and adds to our existing scientific and medical expertise in the areas of gastroenterology and nuclear medicine. As we look ahead to this year, we expect to add expertise in other therapeutic areas including oncology, as well as expand our footprint into multiple geographical areas.” Dr. Perminder Bhatia is a board-certified Neurologist, Principal Investigator for Clinical Trials and Director at the Neuropain Medical Center in Fresno, CA, which he founded in 2003. He is also on staff at Community Health System, Fresno and the Saint Agnes Medical Center where he previously served as Chief, Division of Neurology. Previously, Dr. Bhatia was the Vice Chief, Department of Medicine at Rideout Memorial Hospital. Since 2003, Dr. Bhatia has completed more than 100 clinical trials and has published numerous research papers. He completed his MBBS from Punjab, India and received his Doctor of Medicine from the Albert Einstein College of Medicine. He completed his Neurology Specialty Residency from The State University of New York at Buffalo. “At the Neuropain Medical Center, we pride ourselves on compassionate care by providing clinical trial access for patients to…